Comparative Pharmacology
Head-to-head clinical analysis: CHRONULAC versus MIRALAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHRONULAC versus MIRALAX.
CHRONULAC vs MIRALAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic pH, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Polyethylene glycol 3350 (PEG 3350) is an osmotic laxative that works by retaining water in the stool through hydrogen bonding, increasing fecal water content and promoting bowel movements.
10-30 mL orally once daily to twice daily; for acute constipation, 20-30 mL initially; for hepatic encephalopathy, 30-60 mL every 1-2 hours to achieve 2-3 soft stools daily.
17 g (1 heaping tablespoon) dissolved in 4–8 oz of water, juice, soda, coffee, or tea, administered orally once daily. Maximum duration of use: 7 days.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Not applicable; polyethylene glycol 3350 is minimally absorbed and systemic half-life is not clinically relevant.
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Primarily excreted unchanged in feces (>90% of oral dose); negligible renal elimination (<0.1% recovered in urine).
Category C
Category C
Osmotic Laxative
Osmotic Laxative